EXOME

all the information, none of the junk | biotech • healthcare • life sciences

Fresh Off New Funding Round, FluGen Plans 3 Clinical Trials for 2018

(Page 2 of 2)

Francisco, CA-based Vaxart, which is developing an oral flu vaccine.

However, neither Vaxart nor any other business that Radspinner knows of uses the same technology as RedeeFlu. The vaccine is made up of a replicating live flu virus from which a key gene has been deleted. The vaccine virus is able to live in the body just long enough to provoke a strong immune response, but thanks to the deleted gene it’s not able to cause disease or spread to other people.

“The live virus, single-replication—we’re the only one in the game there,” Radspinner says.

Single PageCurrently on Page: 1 2 previous page